Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC)

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893–917.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56:584–91.
   PubMed Web of Science ®Google Scholar
• Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32.
   PubMed Web of Science ®Google Scholar
• Bul M, Schröder FH. Screening for prostate cancer – the controversy continues, but can it be resolved?Acta Oncol 2011;50(Suppl 1):4–11.
   PubMedGoogle Scholar
• Berg CD. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context. Acta Oncol 2011;50(Suppl 1):12–7.
   PubMedGoogle Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd,Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–32.
   PubMed Web of Science ®Google Scholar
• Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: An updated Cochrane systematic review. Br J Urol Int 2011;107:882–91.
   Google Scholar
• Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schröder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998;90:925–31.
   PubMed Web of Science ®Google Scholar
• Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. Br J Urol Int 2006;98: 777–82.
   Google Scholar
• Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, et al. Impact of prostate cancer testing: An evaluation of the emotional consequences of a negative biopsy result. Br J Cancer 2010;102:1335–40.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, et al. The story of the European Randomized Study of Screening for Prostate Cancer. Br J Urol Int 2003;92(Suppl 2):1–13.
   Google Scholar
• Finne P, Stenman U-H, Määttänen L, Mäkinen T, Tammela TL, Martikainen P, et al. The Finnish trial of prostate cancer screening: Where are we now?Br J Urol Int 2003;92(Suppl 2):22–6.
   Google Scholar
• Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217–27.
   PubMedGoogle Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
   Google Scholar
• Aalto AM, Aro AR, Teperi J. RAND-36 as a measure of health-related quality of life: Reliabilty, construct validity and reference values in the Finnish general population. Helsinki: Stakes; 1999.
   Google Scholar
• Collins RE, Lopez LM, Marteau TM. Emotional impact of screening: A systematic review and meta-analysis. BMC Public Health 2011;11:752.
   Google Scholar
• Awsare NS, Green JSA, Aldwinckle B, Hanbury DC, Boustead GB, McNicholas TA. The measurement of psychological distress in men being investigated for the presence of prostate cancer. Prostate Cancer Prostatic Dis 2008;11:384–9.
   PubMed Web of Science ®Google Scholar
• Wardle FJ, Collins F, Pernet AL, Whitehead MI, Bourne TH, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993;85:653–7.
   PubMed Web of Science ®Google Scholar
• Macefield RC, Lane JA, Metcalfe C, Down L, Neal DE, Hamdy FC, et al. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?Eur J Cancer 2009;45: 2569–73.
   PubMed Web of Science ®Google Scholar
• Essink-Bot ML, Korfage IJ, De Koning HJ. Including the quality-of-life effects in the evaluation of prostate cancer screening: Expert opinions revisited?Br J Urol Int 2003; 92(Suppl 2):101–5.
   Google Scholar
• Fowler FJ, Barry MJ, Walker-Corkery B, Caubet J-F, Bates DW, Lee JM, et al. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioural, and medical care outcomes. J Gen Intern Med 2006;21:715–21.
   PubMed Web of Science ®Google Scholar
• Katz DA, Jarred DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 2007;69: 215–20.
   PubMed Web of Science ®Google Scholar
• Chan EC, Vernon SW, O’Donnell FT, Ahn C, Greisinger A, Aga DW. Informed consent for cancer screening with prostate-specific antigen: How well are men getting the message?Am J Public Health 2003;93:779–85.
   PubMed Web of Science ®Google Scholar
• Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001;16:391–8.
   PubMed Web of Science ®Google Scholar